Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Phosphagenics extends transdermal technology platform

March 9, 2007

Flurizan shows benefit in mild Alzheimer's patients

March 8, 2007

Amarin acquires rights to nasal lorazepam for emergency epilepsy seizures

March 8, 2007

Enrollment completed in phase IIb study of AeroLEF

March 8, 2007

Financing at TransOral to support Intermezzo NDA filing

March 8, 2007

Encouraging proof-of-concept results for PA-325

March 8, 2007

New agents for treating neurological disorders disclosed in recent patent literature

March 8, 2007

MEM-1003 shows no efficacy in bipolar mania

March 7, 2007

Significant pain relief demonstrated in phase IIb study of Fentanyl TAIFUN

March 7, 2007

APD-125 begins phase II for insomnia

March 7, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...